{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T22:01:25Z","timestamp":1771711285396,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.vaccine.2022.10.084","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:31:19Z","timestamp":1667781079000},"page":"7579-7585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Guillain-Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Australia"],"prefix":"10.1016","volume":"40","author":[{"given":"Joshua","family":"Osowicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazel J.","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim P.","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Kiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel W.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.084_b0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.5694\/mja12.10534","article-title":"Guillain-Barre syndrome following pandemic (H1N1) 2009 influenza A immunisation in Victoria: a self-controlled case series","volume":"197","author":"Crawford","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2022.10.084_b0010","unstructured":"Priority list of adverse events of special interest: COVID-19. 2020. (Accessed May 23, 2022, at https:\/\/brightoncollaboration.us\/priority-list-aesi-covid\/.)."},{"key":"10.1016\/j.vaccine.2022.10.084_b0015","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.10.084_b0020","doi-asserted-by":"crossref","unstructured":"Population-based analysis of the epidemiological features of COVID-19 epidemics in Victoria, Australia, January 2020 - March 2021, and their suppression through comprehensive control strategies. Lancet Reg Health West Pac 2021;17:100297.","DOI":"10.1016\/j.lanwpc.2021.100297"},{"key":"10.1016\/j.vaccine.2022.10.084_b0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40264-017-0520-7","article-title":"Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria","volume":"40","author":"Clothier","year":"2017","journal-title":"Australia Drug Saf"},{"key":"10.1016\/j.vaccine.2022.10.084_b0030","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/ije\/dyab101","article-title":"Changes in infection-related hospitalizations in children following pandemic restrictions: an interrupted time-series analysis of total population data","volume":"50","author":"Todd","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2022.10.084_b0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.33321\/cdi.2011.35.28","article-title":"Surveillance of adverse events following immunisation: the model of SAEFVIC","volume":"35","author":"Clothier","year":"2011","journal-title":"Victoria Commun Dis Intell Q Rep"},{"key":"10.1016\/j.vaccine.2022.10.084_b0040","first-page":"1","article-title":"Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines","author":"Gordon","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.084_b0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barre syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2022.10.084_b0050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.084_b0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","article-title":"Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale","volume":"14","author":"van Nes","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.vaccine.2022.10.084_b0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2022.10.084_b0065","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1016\/j.vaccine.2010.04.021","article-title":"Use of the Australian Childhood Immunisation Register for vaccine safety data linkage","volume":"28","author":"Gold","year":"2010","journal-title":"Vaccine"},{"issue":"247\u20139","key":"10.1016\/j.vaccine.2022.10.084_b0070","first-page":"e1","article-title":"COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)","volume":"214","author":"Tuckerman","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2022.10.084_b0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5694\/mja12.11751","article-title":"Human papillomavirus vaccine in boys: background rates of potential adverse events","volume":"198","author":"Clothier","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2022.10.084_b0080","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1016\/j.vaccine.2021.10.030","article-title":"Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria","volume":"39","author":"Gordon","year":"2021","journal-title":"Australia Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.084_b0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0404.2004.00272.x","article-title":"Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996","volume":"110","author":"Bogliun","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.vaccine.2022.10.084_b0090","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5694\/mja12.11087","article-title":"The self-controlled case series method for evaluating safety of vaccines","volume":"197","author":"Hawken","year":"2012","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2022.10.084_b0095","doi-asserted-by":"crossref","first-page":"e068373","DOI":"10.1136\/bmj-2021-068373","article-title":"Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis","volume":"376","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.10.084_b0100","article-title":"The neurological safety of covid-19 vaccines","volume":"376","author":"Pottegard","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.10.084_b0105","doi-asserted-by":"crossref","first-page":"e228879","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barre Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2022.10.084_b0110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15585\/mmwr.mm7103a4","article-title":"Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021","volume":"71","author":"Oliver","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.10.084_b0115","unstructured":"COVID-19 vaccine weekly safety report - 05-05-2022. 2022. (Accessed May 23, 2022, at https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-05-05-2022.)."},{"key":"10.1016\/j.vaccine.2022.10.084_b0120","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1016\/j.vaccine.2008.09.002","article-title":"Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization","volume":"26","author":"Kohl","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.084_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.vaccine.2022.10.084_b0130","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2022.10.084_b0135","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/INF.0000000000002785","article-title":"Progress Toward a Global Vaccine Data Network","volume":"39","author":"Petousis-Harris","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.10.084_b0140","unstructured":"International Network of Special Immunization Services. Canadian Center for Vaccinology, 2022. (Accessed May 23, 2022, at https:\/\/insisvaccine.org.)."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:20:12Z","timestamp":1759404012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0264410X22013664"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guillain-Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}